Patents by Inventor Meredith O'Keeffe
Meredith O'Keeffe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9149515Abstract: A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity.Type: GrantFiled: June 3, 2011Date of Patent: October 6, 2015Assignee: BAVARIAN NORDIC A/SInventors: Meredith O'Keeffe, Hubertus Hochrein
-
Patent number: 8961998Abstract: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: GrantFiled: August 20, 2012Date of Patent: February 24, 2015Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20130216572Abstract: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: ApplicationFiled: August 20, 2012Publication date: August 22, 2013Inventors: Hubertus HOCHREIN, Meredith O'KEEFFE
-
Patent number: 8445275Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor (M-CSF) is provided. M-CSF induces DCs to differentiate into Subtypes, for example plasmacytoid DCs and conventional DCs. Said differentiation is independent of Fms-like-Tyrosine-Kinase 3-Ligand (FL) and/or Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF). Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for Cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: GrantFiled: April 25, 2008Date of Patent: May 21, 2013Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20130122044Abstract: A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity.Type: ApplicationFiled: June 3, 2011Publication date: May 16, 2013Inventors: Meredith O'Keeffe, Hubertus Hochrein
-
Patent number: 8354275Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: GrantFiled: September 21, 2011Date of Patent: January 15, 2013Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Patent number: 8268327Abstract: The invention relates to the methods and kits comprising modified vaccinia virus Ankara (MVA) to provide immediate protection against pathogens. MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: GrantFiled: February 6, 2008Date of Patent: September 18, 2012Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Patent number: 8268328Abstract: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: GrantFiled: April 25, 2008Date of Patent: September 18, 2012Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20120010597Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: ApplicationFiled: September 21, 2011Publication date: January 12, 2012Applicant: BAVARIAN NORDIC A/SInventors: Hubertus HOCHREIN, Meredith O'KEEFFE
-
Patent number: 8053234Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: GrantFiled: April 27, 2007Date of Patent: November 8, 2011Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20110177114Abstract: The invention relates to the methods and kits comprising modified vaccinia virus Ankara (MVA) to provide immediate protection against pathogens. MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: ApplicationFiled: February 6, 2008Publication date: July 21, 2011Inventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20100167332Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor (M-CSF) is provided. M-CSF induces DCs to differentiate into Subtypes, for example plasmacytoid DCs and conventional DCs. Said differentiation is independent of Fms-like-Tyrosine- Kinase 3-Ligand (FL) and/or Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF). Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for Cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: ApplicationFiled: April 25, 2008Publication date: July 1, 2010Applicant: BAVARIAN NORDIC A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20100129404Abstract: The invention relates to methods and kits comprising poxviruses including, but not limited to modified vaccinia virus Ankara (MVA) and uses thereof to provide immediate protection against pathogens. Poxviruses including, but not limited to MVA can be delivered to a host animal just prior to or after exposure to a pathogen and provide protection against the pathogen.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Inventors: Hubertus Hochrein, Meredith O'keeffe
-
Publication number: 20090148405Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor Receptor Ligand is provided. M-CSF receptor ligands induce DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with an M-CSF receptor ligand can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF receptor ligand-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF receptor ligands can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: ApplicationFiled: December 22, 2008Publication date: June 11, 2009Inventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20080267994Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: ApplicationFiled: April 27, 2007Publication date: October 30, 2008Inventors: Hubertus Hochrein, Meredith O'Keeffe
-
Publication number: 20070148129Abstract: The present invention relates generally to therapeutic agents and methods which enhance or otherwise maintain a state of immune tolerance in a subject. The present invention further provides agents and methods for preventing or at least delaying onset of an autoimmune disease such as but not limited to autoimmune diabetes. Furthermore, the agents and methods of the present invention are useful in enhancing the effectiveness of vaccine regimes such as against cancer cells or pathogenic organisms and viruses or for generally enhancing the immune responsiveness against such entities. The present invention further enables the prevention of pathogenic agent-induced autoimmune conditions.Type: ApplicationFiled: December 23, 2004Publication date: June 28, 2007Applicant: THE WALTER AND ELIZA HALL INSTIUTE OF MEDICAL RESEARCHInventors: Ken Shortman, Meredith O'Keeffe, Ben Fancke, Len Harrison, Ray Steptoe, David Vremec